Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. 2007

M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
Department of Pathology and Laboratory Medicine, Nuclear Medicine Laboratory, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Michael.J.Duffy@ucd.ie

The aim of this article is to present updated guidelines for the use of serum, tissue and faecal markers in colorectal cancer (CRC). Lack of specificity and sensitivity preclude the use of all existing serum markers for the early detection of CRC. For patients with stage II or stage III CRC who may be candidates for either liver resection or systemic treatment should recurrence develop, CEA should be measured every 2-3 months for at least 3 years after diagnosis. Insufficient evidence exists to recommend routine use of tissue factors such as thymidylate synthase, microsatellite instability (MSI), p53, K-ras and deleted in colon cancer (DCC) for either determining prognosis or predicting response to therapy in patients with CRC. Microsatellite instability, however, may be used as a pre-screen for patients with suspected hereditary non-polyposis colorectal cancer. Faecal occult blood testing but not faecal DNA markers may be used to screen asymptomatic subjects 50 years or older for early CRC.

UI MeSH Term Description Entries
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009780 Occult Blood Chemical, spectroscopic, or microscopic detection of extremely small amounts of blood. Fecal Occult Blood Test,Blood, Occult
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013940 Thymidylate Synthase An enzyme of the transferase class that catalyzes the reaction 5,10-methylenetetrahydrofolate and dUMP to dihydrofolate and dTMP in the synthesis of thymidine triphosphate. (From Dorland, 27th ed) EC 2.1.1.45. Thymidylate Synthetase,Synthase, Thymidylate,Synthetase, Thymidylate
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 1999, Anticancer research,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 1999, Anticancer research,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 1999, Anticancer research,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 1999, Anticancer research,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 1999, Anticancer research,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
April 2017, European journal of cancer (Oxford, England : 1990),
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 1999, Anticancer research,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 1999, Anticancer research,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
March 2010, Annals of oncology : official journal of the European Society for Medical Oncology,
M J Duffy, and A van Dalen, and C Haglund, and L Hansson, and E Holinski-Feder, and R Klapdor, and R Lamerz, and P Peltomaki, and C Sturgeon, and O Topolcan
January 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Copied contents to your clipboard!